DBV Technologies S.A. (NASDAQ:DBVT) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of DBV Technologies S.A. (NASDAQ:DBVT) have been assigned an average recommendation of “Moderate Buy” from the nine ratings firms that are covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, one has given a hold recommendation, four have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $38.65.

DBVT has been the topic of several recent analyst reports. Wall Street Zen lowered DBV Technologies from a “hold” rating to a “sell” rating in a research report on Saturday. Weiss Ratings restated a “sell (e+)” rating on shares of DBV Technologies in a research report on Monday, December 29th. Guggenheim reaffirmed a “buy” rating and set a $51.00 target price on shares of DBV Technologies in a research note on Friday. HC Wainwright set a $40.00 target price on DBV Technologies in a report on Thursday, December 18th. Finally, Cantor Fitzgerald set a $48.00 price target on shares of DBV Technologies in a report on Wednesday, December 17th.

Institutional Investors Weigh In On DBV Technologies

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DBVT. Allworth Financial LP purchased a new position in shares of DBV Technologies during the 4th quarter valued at $32,000. Royal Bank of Canada purchased a new stake in shares of DBV Technologies during the fourth quarter worth $34,000. New York State Common Retirement Fund acquired a new stake in DBV Technologies during the third quarter valued at $34,000. GAMMA Investing LLC boosted its position in DBV Technologies by 38.4% during the fourth quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock valued at $51,000 after purchasing an additional 744 shares during the last quarter. Finally, Truvestments Capital LLC grew its stake in DBV Technologies by 71.3% in the fourth quarter. Truvestments Capital LLC now owns 3,892 shares of the company’s stock valued at $75,000 after purchasing an additional 1,620 shares in the last quarter. Hedge funds and other institutional investors own 71.74% of the company’s stock.

DBV Technologies News Summary

Here are the key news stories impacting DBV Technologies this week:

• Positive Sentiment: VIASKIN peanut patch nearing FDA submission — media coverage highlights management preparing for a BLA/approval pathway and positions the peanut patch as a potential near-term commercial catalyst. DBV Technologies sets stage for ‘swift’ success as breakthrough peanut patch nears FDA submission
• Positive Sentiment: Citizens Jmp raised its price target to $47 and assigned a “market outperform” rating, signaling strong analyst conviction and implying substantial upside from current levels. Citizens Jmp price target raise
• Positive Sentiment: Guggenheim reaffirmed a “buy” rating and set a $51 price target, another high-end analyst endorsement that supports the bullish narrative around the peanut patch program. Guggenheim reiterates buy
• Positive Sentiment: Financial and operational update: DBV reports progress in toddler and child VIASKIN trials, strengthened leadership ahead of BLA submission, and disclosed cash of $194M plus $94M of additional proceeds (funding into Q2 2027) — improving near-term runway for regulatory activities. DBV Technologies Reports Full Year 2025 Financial Results and Business Update
• Neutral Sentiment: Regulatory/filing housekeeping — DBV filed its 2025 Form 10-K and Universal Registration Document (URD), making audited results and governance disclosures available to investors. This is procedural but important for due diligence. DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document
• Negative Sentiment: Quarterly results significantly missed expectations: EPS of ($4.43) vs. consensus ($0.19) and revenue $0.64M vs. $1.06M expected — very wide losses and negative margins raise near-term valuation and funding-scenario concerns despite the stated cash runway. DBV Technologies quarterly earnings press release

DBV Technologies Stock Performance

NASDAQ DBVT opened at $20.00 on Friday. The firm’s 50 day moving average price is $21.58 and its two-hundred day moving average price is $17.28. DBV Technologies has a twelve month low of $5.30 and a twelve month high of $26.18. The stock has a market cap of $1.11 billion, a price-to-earnings ratio of -3.83 and a beta of -0.97.

DBV Technologies (NASDAQ:DBVT) last released its earnings results on Thursday, March 26th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.96). The business had revenue of $0.64 million during the quarter, compared to analysts’ expectations of $1.06 million. DBV Technologies had a negative net margin of 2,606.83% and a negative return on equity of 310.56%. On average, research analysts forecast that DBV Technologies will post -7.05 EPS for the current fiscal year.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.